Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 20, 2017 04:05 ET | Source: Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Announces Two Singapore Approvals for Microcyn® (hypochlorous acid) for the Treatment of Atopic Dermatitis and Hypertrophic / Keloid Scars

PETALUMA, Calif., June 20, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...
June 05, 2017 16:05 ET | Source: Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Reports Financial Results for Fourth Quarter and Fiscal Year 2017

Product revenue for fourth quarter up 60% and for fiscal year 2017 up 48%, compared to last year, driven by growth in U.S. dermatology salesCash position of $17.5 million; management believes the...
June 02, 2017 04:05 ET | Source: Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Announces Fiscal Year/Fourth Quarter 2017 Financial Results and Conference Call

PETALUMA, Calif., June 02, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that the financial results for its fiscal year and fourth quarter...
April 12, 2017 04:05 ET | Source: Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Receives Two New United Arab Emirates Regulatory Approvals: Pediacyn® for Atopic Dermatitis and Epicyn® for Scar Management

PETALUMA, Calif., April 12, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...
March 29, 2017 04:05 ET | Source: Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Receives U.S. FDA Clearance of Loyon® Skin Descaler for Relief of Scaling Associated with Various Dermatoses

PETALUMA, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...
March 23, 2017 04:05 ET | Source: Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Receives Final $1.5 Million Payment From Sale of Latin America Business to Invekra S.A.P.I. de C.V.

PETALUMA, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...
March 16, 2017 04:05 ET | Source: Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Announces Results from SebuDerm™ Gel Study in Treatment of Seborrheic Dermatitis

Evaluation of SebuDerm (hypochlorous acid) Gel on Mild to Moderate Facial and Scalp Seborrheic DermatitisInvestigator Global Assessment (IGA) Scores Showed a 33% Improvement at Day 14 and a 52%...
February 28, 2017 04:05 ET | Source: Sonoma Pharmaceuticals, Inc.

PetSmart® Launches the MicrocynAH® Family of Pet Healthcare Products for Dogs, Cats, Birds, Reptiles and Small Animals

PHOENIX and PETALUMA, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that PetSmart, Inc., the leading pet specialty retailer...
February 09, 2017 16:05 ET | Source: Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Reports Financial Results for Fiscal Third Quarter 2017

U.S. Product Revenue up 65%, Driven by Growth in U.S. Dermatology SalesCash Position of $20.5 Million; More Than Fully Funded to Achieve EBITDA Breakeven Income From Discontinued Operations of...
January 31, 2017 04:05 ET | Source: Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Appoints Marc Umscheid as Chief Strategy and Marketing Officer

PETALUMA, Calif., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced the appointment of Marc Umscheid as chief strategy and marketing...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right